Notch

RC Show 2024 Release New & Innovative Product Showcase

Retrieved on: 
Wednesday, March 27, 2024
Cooking, LFC, PFAS, Milk, Pineapple, Enercare Centre, Carbon, Wine, Pea, Restaurant, Creativity, Marketing, Automation, Red meat, Ginger, Drink, Miski, Hormone, VKD, Atlas, Freezing, Notch, Woman, Mouth, Safety, Interim, Cholesterol, Sambucus, Breakfast, Food, Rejuvenation, Taste, Bison, Coffee, RC, Plant, Food safety, Advertising, Farmer, Growth, ServiceNow, SoFi, Environment, Agave, Robotics, Water, Billio, MEIKO, AMT, Genetically modified organism, Tractor

Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.

Key Points: 
  • Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.
  • With a comprehensive range including advertising, delivery, hotel, and the latest addition, cleaning robots, they cater to diverse commercial needs.
  • Diversey Canada Inc. has been a pivotal player in increasing operational efficiency for the industry and that continues in 2024.
  • You will find more of these innovative products and solutions all under one roof at RC Show 2024, taking place April 8-10, where the industry will come together, be inspired and learn how to LEVEL UP!

Expel Unveils Updated NIST CSF 2.0 Getting Started Toolkit to Help Companies on their Security Maturity Journey

Retrieved on: 
Wednesday, March 13, 2024
Software, Networks, Data Analytics, Internet, Data Management, Professional Services, Technology, Security, CSF, Notch, NIST, Version 2.0, SANS Institute, MDR, Investment, Risk management

Expel , the leading managed detection and response (MDR) provider, today unveiled the updated version of its National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) Getting Started toolkit .

Key Points: 
  • Expel , the leading managed detection and response (MDR) provider, today unveiled the updated version of its National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) Getting Started toolkit .
  • The kit, which includes a “getting started” guide and a self-scoring spreadsheet, helps security leaders and operators assess their cybersecurity postures, aligned with the recently released version 2.0 of the NIST CSF.
  • “Over the last decade, the NIST CSF has been a critical tool for companies in determining their cybersecurity readiness and assessing where they can improve—and version 2.0 expands on that foundation,” said Greg Notch, Chief Information Security Officer, Expel.
  • Expel’s NIST CSF guide helps security leaders and operators understand how to approach the framework and make sense of its functions, categories, subcategories, and tiers.

Blocking Abnormal Stem Cell Signal during Aging Lessens Related Bone Loss

Retrieved on: 
Wednesday, September 27, 2023
Skeleton, Osteoporosis, Bone marrow, Adipocyte, Doctor of Philosophy, National Institutes of Health, Bangladesh Technical Education Board, B cell, Pharmacotherapy, Protein, MD, Ageing, Orthopedic surgery, Disease, Tissue, University, Therapy, NYU, Research, University college, Osteoblast, Nicastrin, Fracture, Heterochromatin, DNA, Cancer, New York University Grossman School of Medicine, Multimedia, Cell, Steatosis, Max Planck Institute for Molecular Biomedicine, Miami Shores, Florida, Max Planck Society, Laura, Patricia, RNA, NYU Langone Health, Morphogenesis, Cell biology, Mouse, New York University College of Dentistry, Gene, Mobile phone, Phosphorus, Dentistry, EFF, SSPC, Pathology, Notch, Nature, Isaac Leucht

The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.

Key Points: 
  • The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.
  • The study results revolve around immature stem cells, which have the capacity to mature into more than one cell type.
  • Aging is known to come with loss of the ability of stem cells to become bone-making cells, with related skeletal deterioration among the most common causes of age-associated impairment.
  • "Our newly gained knowledge opens potential therapeutic avenues to overcome age-related bone loss by manipulating down-stream effectors for Notch signaling in these stem cells."

Christie Pandoras Box Software powers LED video walls at American carmaker's corporate lobby in Shanghai

Retrieved on: 
Saturday, July 22, 2023
The Pandoras, Christie, Pandora's box, Software, Christie's, LED, Knowledge, Environment, White box (software engineering), Music, Television, Notch

SHANGHAI, July 22, 2023 /PRNewswire-PRWeb/ -- Christie® is pleased to announce that its award-winning Pandoras Box® Software is powering three large LED video walls in the lobby of the corporate headquarters of an American carmaker in Shanghai.

Key Points: 
  • SHANGHAI, July 22, 2023 /PRNewswire-PRWeb/ -- Christie® is pleased to announce that its award-winning Pandoras Box® Software is powering three large LED video walls in the lobby of the corporate headquarters of an American carmaker in Shanghai.
  • Christie Pandoras Box Software was chosen for its powerful yet cost-effective playback and show control capabilities.
  • "We are excited to collaborate with an automobile manufacturer to deploy Christie Pandoras Box Software in its contemporary corporate lobby," said Daniel Xu, representative of Marvel Vision.
  • April Qin, senior sales director for China, Enterprise, Christie, commented, "we are thrilled to see how Christie Pandoras Box Software has transformed the visitor and employee experience in the carmaker's corporate lobby in Shanghai.

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

Retrieved on: 
Thursday, April 27, 2023
Carcinoma, Partnership, Drug development, Therapy, Glomus tumor, Lung cancer, Doctor of Philosophy, SCLC, DLL3, HKEX, Patient, ADC, Spacecraft, Tumor microenvironment, Pharmaceutical industry, Notch

SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink).

Key Points: 
  • SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink).
  • Through this collaboration, we have expanded our lung cancer franchise and global oncology pipeline with YL212, a novel DLL3 ADC program.
  • We will leverage our capabilities to advance the global development of YL212,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development at Zai Lab.
  • We are glad to collaborate with Zai Lab and look forward to bringing this innovative therapy to patients worldwide.”

Notch Researchers Develop Improved Model for Predicting CAR-T Clinical Pharmacology and Response to Advance Next-Generation Product Design; Results Published in Nature Biotechnology

Retrieved on: 
Monday, February 27, 2023
Systems biology, Infection, Tissue, Biotechnology, Nature Biotechnology, IPSC, Therapy, Neoplasm, Doctor of Philosophy, Cancer, Pharmacology, Immune system, Patient, Vaccine, Medical imaging, Notch

The paper, entitled, "Deconvolution of clinical variance in CAR-T cell pharmacology and response," documents a new model that is expected to help accelerate the design of next-generation CAR-T products, including those derived from iPSCs.

Key Points: 
  • The paper, entitled, "Deconvolution of clinical variance in CAR-T cell pharmacology and response," documents a new model that is expected to help accelerate the design of next-generation CAR-T products, including those derived from iPSCs.
  • Engineered CAR-T cells—"living drugs" that circulate in patients' immune systems—present distinctive challenges compared with development of small-molecule drugs or biologics.
  • Using clinical pharmacokinetic and tumor dynamic data from approved CAR-T therapies in different hematologic malignancies, the researchers discovered the primary determinants of CAR-T expansion, persistence, and anti-tumor response.
  • "We expect this mechanism-based model for predicting clinical response in patients to enable a new phase of predictive CAR-T product development, including for T cells derived from renewable sources like iPSCs."

Notch announces $10M in funding led by Portage to help hospitality businesses digitize their operations

Retrieved on: 
Thursday, January 19, 2023
COVID-19, Commerce, AP, Marketing, Growth, Software, Restaurant, Golden Venture, Cassette tape, Online shopping, Accomplice, Notch

The investment was led by Portage, with participation from Golden Ventures, Math Ventures, Accomplice, Pre-Cursor Ventures, Garage Capital and Plexo Capital.

Key Points: 
  • The investment was led by Portage, with participation from Golden Ventures, Math Ventures, Accomplice, Pre-Cursor Ventures, Garage Capital and Plexo Capital.
  • Notch re-branded as a software solution to help restaurants digitize their back of house operations.
  • As part of the financing, Ricky Lai, Partner at Portage, will be joining the Board of Directors at Notch.
  • Notch will use this additional funding to ramp up the sales and marketing teams, and fuel geographic expansion for the company.

Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

Retrieved on: 
Tuesday, November 8, 2022
Review, B cell, Biomedical engineering, UCLA, Developmental Biology (journal), Health, MD, Bachelor of Engineering, Systems biology, Biotechnology, Cancer, Stem cell, Mesoderm, Molecular genetics, Hannover Medical School, GMP, Placenta, CAR, SAB, IPSC, University, Synthetic biology, Doctor of Philosophy, University of Toronto, Inherited disorders of trafficking, Biomedicine, HSC, United States Air Force Scientific Advisory Board, University of Wisconsin–Madison, Genome, Cell, Research, Therapy, Tumor microenvironment, CD34, Developmental biology, Automation, CEO, Management, Vaccine, BC, Microbiology, Notch, Immunology

VANCOUVER, BC, Nov. 8, 2022 /PRNewswire/ -- Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to welcome new members to its Scientific Advisory Board (SAB). Joining existing SAB members—Peter Zandstra, PhD; Juan Carlos Zúñiga-Pflücker, PhD; and Yvonne Chen, PhD—are Kris Saha, PhD; Hanna Mikkola, MD, PhD; and Robert Zweigerdt, PhD; who will review and provide input, opinion, and expertise into Notch's research endeavors. Notch thanks outgoing SAB members Chris Sturgeon, PhD; Marcel van den Brink, MD, PhD; and Jeff Hubbell, PhD for their contributions.

Key Points: 
  • Notch thanks outgoing SAB members Chris Sturgeon, PhD; Marcel van den Brink, MD, PhD; and Jeff Hubbell, PhD for their contributions.
  • "Notch's leadership team, at every level, comprises some of the best minds in preclinical science, advanced cell manufacturing, bioengineering, and systems biology," observes David Main, Notch's President and CEO.
  • "The members of our SAB are working at the frontiers of scientific and technology discovery, responding to unique, complex challenges that are highly relevant to our work at Notch.
  • Learn more at http://yvchen.bol.ucla.edu/
    Hanna Mikkola, MD, PhD | Professor of Molecular, Cell, and Developmental Biology, UCLA:Dr. Mikkola's research focuses on the microenvironmental cues driving blood lineage development.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022
People, Adenoid cystic carcinoma, Safety, Quality of life, Patient, Physician, Oncology, Abdominal wall, Nasdaq, Multiple myeloma, PR, ESMO, Aggressive fibromatosis, Treatment, ACC, Head, Organ dysfunction, European Society for Medical Oncology, RECIST, Pivotal, Plantar fibromatosis, FDA, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, MM, AYLA, DOR, Royal Marsden Hospital, QOL, Progression-free survival, GLOBE, Congress, Therapy, Incidence, Doctor of Philosophy, MRI, Cancer, ORR, T-ALL, PFS, Chronic pain, Recurrence, Pharmaceutical industry, Medical imaging, Public relations, Notch, Part

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

Amyloid Precursor Protein Secretase Inhibitors Pipeline Market Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, August 1, 2022
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amyloid beta, Brain, III, Food, Route, GSI, Discovery, Alzheimer's disease, Adenoid cystic carcinoma, Therapy, News, Clinical trial, ACC, AD, US Foods, Administration, FDA, Aggressive fibromatosis, Patient, Drug, Route of administration, II, Plantar fibromatosis, Petrochemical, Medical imaging, Fine chemical, Pharmaceutical industry, Notch, Adenoid, Amyloid

This "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.

Key Points: 
  • This "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.
  • Amyloid precursor protein secretase inhibitors: Emerging Drugs Chapters
    This segment of the Amyloid precursor protein secretase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • Amyloid precursor protein secretase inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Amyloid precursor protein secretase inhibitors drugs segregated based on following parameters that define the scope of the report.
  • Amyloid precursor protein secretase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.